Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Schedule Of Segment Loss Significant Segment Expenses

The following table represents information about segment loss and significant segment expenses (in thousands):


	Three Months Ended March 31,
	2026		2025
Direct research and development expenses by program:
AP01	$	13,155	$	10,939
AP02		4,719		729
AP03		228		351
Unallocated research and development expenses:
Personnel-related (excluding stock-based compensation)		4,063		2,867
Facility and information technology allocated expenses and other research and development costs		320		270
General and administrative expenses:
Personnel-related (excluding stock-based compensation)		2,280		1,459
Facility expenses and information technology		293		147
General corporate expenses and professional fees		1,595		1,402
Other segment items (1)		216		(661	)
Net loss	$	26,869	$	17,503

(1)

For the three months ended March 31, 2026, other segment items consist of $0.9 million of interest income, $0.2 million accretion of marketable securities, $1.2 million of stock-based compensation expense, $0.1 million of interest expense and less than $0.1 million of depreciation expense and other expenses. For the three months ended March 31, 2025, other segment items consist of $0.7 million of interest income, $0.6 million accretion of marketable securities, $0.5 million of stock-based compensation expense, and less than $0.1 million of depreciation expense and other expenses.

Avalyn Pharma Inc. 10-Q